NGL 2026 will bring clinicians, scientists, founders and investors together to turn healthspan ideas into clinical action.

Deepinder Goyal’s brain-wearable startup Temple has acquired Longevous, pulling the cofounders into full-time roles steering ...

Mission Therapeutics pairs brain-penetrant mitochondria drug with NeuraLight’s eye-tracking biomarkers in a multi-country ...

A new industry analysis maps 30-plus microbiome startups against longevity, and finds a field still torn between wellness and ...

Phase 3 results presented in Munich and Barcelona show gains for two life-threatening conditions that quietly steal years ...

Core Biogenesis and Faravelli are testing whether the biotech behind facial skincare can be scaled up to treat the rest of ...

Sam Altman-backed Retro Biosciences is widening its Alzheimer’s trial after early doses showed no red flags. Most drug trials ...

New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing ...

Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.

Six proteomic clocks detect a younger biological age signal in an IPF trial – but separating geroprotection from treatment ...

Leisure exercise lowers dementia risk, while physically demanding jobs may raise it – twist that reshapes how we think about ...

Researchers say disrupted sleep may be one of the earliest signs of Alzheimer’s, arriving years before memory loss and ...